With 11 new partners, AACR’s Project GENIE to make available genomic data from 60,000 tumors by 2019 August 03, 2018Vol.44 No.31By Matthew Bin Han Ong
In Brief Christiana Care Gene Editing Institute, NovellusDx form personalized medicine partnership July 28, 2018Vol.43 No.30
Conversation with The Cancer Letter Maha Hussain: OS isn’t a practical endpoint in the context where patients are likely to live 10 years or more July 20, 2018Vol.44 No.29By Paul Goldberg
Conversation with The Cancer Letter Julia Beaver: SPARTAN and PROSPER showed MFS improvements greater than 20 months July 20, 2018Vol.44 No.29By Paul Goldberg
FDA spells out rules for new endpoint: Metastasis-free survival July 20, 2018Vol.44 No.29By Paul Goldberg
Conversation with The Cancer Letter Novartis’s Hirawat: “It’s a continuous dialogue that goes on on a daily basis” July 20, 2018Vol.44 No.29By Paul Goldberg
Pilot programs aim to revamp cancer drug approval process—from completion of trial to ODAC presentation July 20, 2018Vol.44 No.29By Paul Goldberg
Drugs & Targets FDA grants breakthrough designation for Tecentriq + Avastin as first-line treatment for hepatocellular carcinoma July 20, 2018Vol.44 No.29
Drugs & Targets BMS and Gritstone to evaluate neoantigen immunotherapy in solid tumors July 20, 2018Vol.44 No.29
